GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT06725693

Recruiting

Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease

Lead sponsor

Tianjin Medical University

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

Enrollment

500

estimated

Study population

Oncology

Key I/E criterion

—

Primary endpoint

•Standardized uptake value (SUV)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06725693

Org study IDTJMUGH-06

Timeline

Milestones

Study start2019-02-01actual

Study first posted2024-12-10actual

Last update posted2025-02-11actual

Primary completion2027-11-01estimated

Study completion2027-11-01estimated

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Oncology

Eligibility

Who can enroll

Minimum age18 Years

Maximum age80 Years

SexAll

Healthy volunteersAccepted

Sampling methodNon probability sample

Study population text

(i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Inclusion criteria

- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion criteria

- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

Standardized uptake value (SUV)

Time frame:30 days

descriptive

Secondary/protocol endpoint/low confidence

Diagnostic efficacy

Time frame:30 days

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Comparison of PET/CT using (68)Ga-NOTA-Exendin-4 with (68)Ga-DOTATATE, (18)F-FDG, and conventional imaging in the localization of insulinomas.
European journal of nuclear medicine and molecular imaging2025 Sep (month)PMID40259061doi:10.1007/s00259-025-07288-xvia clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.